GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- C5518 γ-Linolenic AcidSummary: weak LTB4 receptor antagonist
- C5675 Fendiline (hydrochloride)Summary: α2-adrenergic receptor antagonist
- C5802 CarazololSummary: high-affinity, lipophilic, non-selective ligand of the β-adrenergic receptors
- B1004 ICI 118,551 hydrochlorideSummary: Highly selective β2 adrenergic receptor antagonist
- B1429 Rimonabant3 CitationTarget: CB1 Receptors|CB2 ReceptorsSummary: CB1 receptor antagonist
- B1198 CisaprideTarget: Voltage-gated Potassium (KV) Channels|5-HT4 ReceptorSummary: 5-HT4 receptor agonist
- B1297 SiramesineSummary: Sigma (σ) receptor agonist
- B1005 VilanterolSummary: β2-AR agonist
- B1006 Vilanterol trifenatateSummary: β2-AR agonist
- B2256 SB742457Summary: 5-HT6 receptor antagonist,highly selective and high affinity